SurModics (SRDX) Tops Q2 EPS by 12c; Offers FY22 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. SKYD
6. BBIO
7. SPY
8. RCKT
9. CRWV
10. NVDA

Go back to SurModics (SRDX) Tops Q2 EPS by 12c; Offers FY22 Guidance

Surmodics Reports Second Quarter Fiscal 2022 Results

April 27, 2022 7:30 AM EDT

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2022 second quarter ended March 31, 2022 and updated its financial outlook for its fiscal 2022.

Summary of Second Quarter and Recent Highlights

Revenue of $26.1 million, a sequential increase of 13% Record In Vitro Diagnostics revenue of $7.7 million GAAP EPS of $(0.29), non-GAAP EPS of $(0.22) Double-digit product sales growth year-over-year from both Medical Device and In Vitro... More